arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Zura Bio Ltd

ZURA

$4.32 ▼ -0.19 (-4.21%) at close

6 Visible periods

19 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Zura Bio Ltd faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $406.8M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -58.5% ↘

FCF / Share $-0.69 ↘

Trailing P/E —

Price / Book 3.1x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-68.65M

↓ -31.0% —

FCF / Share Free cash flow per share

$-0.69

↓ -83.9% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
EPS Growth YoY (%)	-76.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	71.3% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	98.5% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	-31.0% Weak ↑ Weak Improving Year-over-year change in net income	13.2% Fair Fair Year-over-year change in net income	-134.9% Weak Weak Year-over-year change in net income	—	—	—
FCF Growth YoY (%)	-83.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	17.6% Good Good Year-over-year change in free cash flow	91.4% Excellent Excellent Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Effective Tax Rate (%) (%)	—	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—
FCF / Net Income (x)	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.25x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.05x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Return on Invested Capital (%)	-58.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-105.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	66.9% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—	—
Return on Capital (%) (%)	-66.0% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-30.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-62.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-516.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	-67.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-551%)	-35.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-338%)	-101.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-778%)	80.2% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+434%)	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Net Debt (USD)	$-109.41M	$-176.50M	$-99.80M	—	$-729.22K	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Basic EPS, GAAP (USD)	$-1.06	$-0.60	$-2.09	$-141.97	—	—
Free Cash Flow per Share (USD)	$-0.69	$-0.37	$-0.46	$-5.27	—	—
Book Value per Share (USD)	$1.38	$2.25	$1.36	$-114.60	—	—
Tangible Book Value per Share (USD)	$1.38	$2.25	$1.36	$-114.60	—	—
Basic Weighted Avg Shares (shares)	94.16M	75.07M	33.06M	228,148	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Working Capital (USD)	$99.90M	$159.23M	$80.54M	$-13.04M	$879.83K	—
Total Equity (USD)	$101.54M	$146.81M	$59.33M	$-32.06M	$-9.18M	$0.00

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Mar 9, 2021 10-K ↗
Depreciation Expense (USD)	$49.00K	$9.00K	—	—	—	—
Net Income, GAAP (USD)	$-68.65M	$-52.40M	$-60.36M	$-25.70M	—	—
Operating Cash Flow (USD)	$-64.81M	$-28.08M	$-15.05M	$-1.20M	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 6 years · 23 quarters

Zura Bio Ltd

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare ZURA with peers